6 Meridian’s Pacira BioSciences PCRX Stock Holding History

6 Meridian’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$219K	Buy	3,637 +37	+1%	+$2.04K	0.02%	356
2021 Q3	$202K	Buy	+3,600	New	+$207K	0.02%	375

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

6 Meridian's PCRX Position: Q4 2021 in Review

6 Meridian increased its Pacira BioSciences (PCRX) stake by 1% in Q4 2021, buying an estimated $2.04K and bringing the position to 3,637 shares worth $219K. The position accounts for 0.02% of the portfolio, ranked #356.

6 Meridian first reported a position in PCRX in Q3 2021 and has held it in 2 quarters since. 276 funds tracked by Wall St. Rank hold PCRX as of Q4 2021.

6 Meridian held 3,637 shares of Pacira BioSciences worth $219K as of Q4 2021.
6 Meridian bought 37 Pacira BioSciences shares in Q4 2021, an estimated $2.04K.
Pacira BioSciences made up 0.02% of 6 Meridian's portfolio in Q4 2021, its #356 holding.
6 Meridian first reported a position in Pacira BioSciences in Q3 2021 and has held it in 2 quarters since.
276 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2021.

Based on 6 Meridian's 13F filing for Q4 2021, filed 1 Feb 2022.